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Abstract:   
Release kinetics of tigecycline, a potential antibiotic in treatment of osteomyelitis, 
from calcium hydroxyapatite (CHA), as one of the most important ceramic materials in bone 
tissue engineering, was investigated in this study. Tigecycline, in solid state, was mixed with 
CHA powder and the obtained mixture was compressed into tablets using two different 
pressures. These tablets were immersed in a phosphate-buffered saline solution and 
tigecycline release was measured by a UV-VIS spectrophotometer. The total release time was 
5 or 28 days, depending on the pressure applied during compression. It was shown that there 
is a close relationship between pore sizes and drug release rate. The drug release kinetics 
was interpreted on the base of pore sizes and pore size distribution.  
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1. Introduction 
 
CHA scaffolds have been widely used as implants in dentistry and orthopedics due to 
their biocompatibility with bone tissue and osteoconductivity [1-3]. Besides, CHA can be 
used as carrier for drug delivery since it is able to absorb different chemical species on its 
surface [4, 5]. Bacterial infections occur frequently during surgical interventions and 
antibiotic administration at the surgical site is of great importance in bone graft surgery 
because the conventional route of antibiotic administration results in low antibiotic level in 
the bone tissue, due to limited antibiotic penetration to the bone [6-8]. High local 
concentrations of antibiotic can be achieved by entrapping the antibiotic into an apatite 
scaffold, from which it would gradually release and ensure protection from bacterial 
infections over a long postoperative period [7, 9, 10]. Thus, CHA acts at the same time as a 
bone substitute material and as a drug delivery device. 
Many bone infections are caused by multi-resistant microorganisms and new 
antimicrobials are needed to repress these resistant bacteria. Therefore, a new class of 
antibiotics, glycylcycline antibiotics, has been developed to overcome the resistance to 
tetracyclines. Best known among them is tigecycline, which seems to be a potential drug in 
treatment of severe orthopedic infections [11-14].  The efficacy of tigecycline in a variety of 
animal infection models for osteomyelitis, endocarditis, pneumonia and peritonitis was shown 
in several studies. When applied in humans, tigecycline was widely distributed in the body 
but its concentration in bone was relatively low, as some studies have shown [12, 14]. One B. Čolović et al. /Science of Sintering, 45 (2013) 107-116 
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study on humans has shown that tigecycline may be used in treatment of chronic 
osteomyelitis resistant Acinetobacter sp [11]. 
Drug release kinetics from CHA cements has not been completely clarified yet and 
none of the existing models describes the whole kinetics of release [1, 15-17]. According to 
many authors, the kinetics of drug release at the initial stage is controlled by surface 
phenomenon, while that of sustained release depends on the penetration depth determined by 
the cement porosity. Thus, the kinetics of drug release is related to the pore size and pore size 
distribution in the cement used [18-21]. 
 
 
2. Materials and methods 
 
2.1. Materials 
 
The apatite powder used in this study was synthesized as follows. First, two precursor 
solutions were prepared: (i) 500 ml of 3.02 cmol aqueous suspension of Ca(OH)2 and (ii) 500 
ml of 2.32 cmol aqueous solution of (NH4)2HPO4. Then, the (NH4)2HPO4 solution was poured 
into the Ca(OH)2 suspension and vigorously stirred. The pH of the so-prepared solution 
mixture was adjusted to 7.4. Finally, this mixture was transferred into a beaker, covered with 
a glass plate, and autoclaved at a temperature of 150 
oC and pressure of 5 bar for 8 h. After 
hydrothermal treatment in the autoclave, the precipitate was decanted, dried at 80 
oC for 48 h, 
ground, washed with deionized water, and ultracentrifuged in order to obtain the purest 
possible CHA. [22] 
 
2.2. Tablet fabrication  
 
Tigecycline, in concentration of 0.5 % w/w, was mixed with CHA powder and 
compressed into tablets with a pressure of 16 and 156 MPa, using a hydraulic press. Tablet 
parameters were: diameter - 10 mm, height -2 mm. 
 
2.3. Tablet evaluation 
 
An X-ray diffraction (XRD) method (Philips PW 1050) with Cu-Kα1−2 radiation was 
used for phase analysis of CHA and determination of crystallite sizes and lattice parameters. 
Data were analyzed in the range of 2θ from 9 to 67◦ with a scanning step of 5◦, and exposition 
time of 2 sec per a step [22]. 
A PERKIN ELMER 983G IR spectrometer, with KBr pastille, was used for CHA 
powder  characterization.  IR  spectra  were  recorded  in  the  wave  number  range  of              
4000–400 cm
−1. 
A scanning electron microscope (SEM JEOL 5300) was used to analyze the 
morphology and size distribution of CHA particles. Samples for SEM analysis were prepared 
as follows: they were suspended in ethanol and dispersed by ultrasound for 10 min, and then 
coated with gold by the PVD process.  
Specific surface areas were measured by nitrogen adsorption at −196  °C using a 
Varian Aerograph (model 920) gas chromatograph equipped with TCD detector. Before the 
measurements, the samples were treated at 150 °C in a helium flow for 2h. After that, a gas 
mixture of 27 vol.% of nitrogen in helium (30 cm
3/min) was passed over the sample and the 
sample cell was cooled by immersion in liquid nitrogen. The cooling sample adsorbed a 
certain amount of nitrogen from the gas stream until adsorption equilibrium was established. 
After removal of the liquid nitrogen bath, the sample was warmed and the adsorbed nitrogen 
released, enriching the effluent monitored by a TCD detector. When desorption was complete, B. Čolović et al./Science of Sintering, 45 (2013) 107-116 
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a known volume of nitrogen (0.5 cm
3) was added to the nitrogen–helium stream. By 
comparing desorption and calibration peaks, the volume of nitrogen adsorbed by the sample 
was calculated and the surface area of the sample determined by “one point” BET method. 
The assumption that the synthesized particles were spheroids enabled the calculation of the 
average radius of particles (dBET = 6/ρSw), where Sw is the specific surface area and ρ = 
3.156 g/cm
3 is the theoretical density of synthesized CHA powders. 
Porosimetry measurements were carried out on a Carlo Erba Porosimeter 2000 using 
the Milestone 200 Software System. This high-pressure mercury intrusion porosimeter 
operates in the interval 0.1−200 MPa, enabling estimation of pores in the range from 7.5 to 
15000 nm. 
 
2.4. Drug release 
 
Tigecycline release was measured after immersion of tablets into 40 ml phosphate 
buffer saline (PBS) at 37°C and continuous stirring. The quantity of released antibiotic was 
measured using a UV-VIS spectrophotometer at the wavelength of 245 nm, by taking 3 ml 
samples at desired time intervals. Withdrawn samples were replaced with 3 ml of fresh PBS.  
 
2.5. Drug release kinetics - general approach  
 
Drug release kinetics depends on many factors: the microstructure of the drug 
delivery device, drug solubility, type of bond between the drug and the device, and, if any, on 
the mechanism of device degradation. Calcium phosphate cements can be treated as non-
biodegradable devices because the rate of drug liberation is much higher than the rate of 
matrix degradation. So, the drug release is controlled by the diffusion process through the 
cement device. [1] 
Equations for drug release from diffusion controlled devices are based on Fick’s 
second diffusion law. A well-known is Higuchi’s equation, based on a pseudo steady-state 
approach:   
Dt C C C A M s s t ) 2 ( 0 − =  ,                                                                                       
where Mt is the amount of drug released for time t; A is the surface area of the device; 
D is the diffusion coefficient of the drug in the matrix; Cs is the solubility of the drug in the 
matrix; C0 is the initial concentration of the drug in the matrix. This equation can describe, at 
least, the initial phase of the release, when about 60% of the total drug amount is released [1, 
15]. 
The Korsmeyer-Peppas model is also used to describe the drug release kinetics, and it 
is also applicable to degrading matrices in which the drug release mechanism often deviates 
from Fick’s law, described by the following equation [16]: 
Mt/M∞= kt
n,                                                                                                               
where Mt is the quantity of drug released at time t, M ∞ is the quantity of drug released at 
infinite time, k is the kinetic constant, while n is the release exponent (for cylindrical matrices 
n: 0.43 to 0.5 (diffusion controlled release) and 0.50 < n <1.0 (anomalous transport). This 
model, too, is generally not applicable after 60% of total drug amount is released [16]. 
 
 
3. Results and discussion 
 
3.1. Phase analysis  
 
The obtained X-ray data (Fig.1.) show that the hydrothermally synthesized powder 
corresponds to carbonated calcium hydroxyapatite Ca10(PO4)6(OH)2 (JCPDS 9–432). All B. Čolović et al. /Science of Sintering, 45 (2013) 107-116 
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characteristic diffraction patterns are present: (211) at 2θ =31.9
o; (112) at 2 θ = 32.26
 o, (3 0 0) 
at 2 θ =33.12
 o, (002) at 2 θ = 25.86
 o, (222) at 2 θ = 46.86
 o, and (213) at 2 θ = 49.58
 o [21]. 
The crystallites size, calculated using Sherer’s equation, is 8-22 nm.          
            
                  
Fig. 1.  X-ray diffraction pattern of hydrothermally synthesized CHA powder 
 
The IR spectrum of the synthesized powder (Fig.2.) shows bands characteristic of 
CHA. The asymmetric stretching (ν3) and bending (ν4) modes of PO4
3− ion were detected at 
about 1092 and 1042 cm
−1, and 603 and 569 cm
−1, respectively; while symmetrical stretching 
modes (ν1 and ν2) of PO4
3− ion were registered at around 957 and 473 cm
−1, respectively. The 
liberation and the stretching mode of OH
− were detected at around 630 and 1626 cm
−1, 
respectively. The stretching vibrations ascribed to CO3
2− at about 1442, 1406 and 875 cm
−1 
are also present. This indicates incorporation of the carbonate group into the apatite structure. 
The band registered at 630 cm
−1 is ascribed to the liberation mode of the OH
− vibration. It is 
evident that type B carbonated hydroxyapatite was obtained and that the replacements at the 
positions of the OH
− ions, revealed by changes in shape and position of the band at 3658 
cm
−1, indicate that these changes were not predominantly caused by the substitution of OH
− 
by CO3
2−. 
 
Fig. 2. IR spectrum of hydrothermally synthesized CHA powder B. Čolović et al./Science of Sintering, 45 (2013) 107-116 
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3.2. SEM  
 
CHA powder consists of agglomerates, which are very similar in shape and size (1 - 
5µm), as it can be seen on the SEM micrograph (Fig.3.). These agglomerates are built up 
from fine particles (~200 nm) and their forms are irregular with oval edges due to spherical 
shapes of individual particles [22]. 
 
 
 
 
Fig. 3. SEM micrograph of CHA powder 
 
 
3.3. SBET and porosimetry 
 
Porosity parameters, obtained using BET method, are given in Table I. The average 
particle diameter, calculated from the specific surface area of CHA powder is 160 nm. 
 
Tab. I Porosity parameters determined by BET method 
 
Sample 
SBET, 
m
2/g 
Total pore volume, 
cm
3/g 
Mean pore diameter 
size, nm 
CHA powder  12  1.00  310 
Tablet 1, p=16 MPa  13  0.39  75 
Tablet 2, p=156 MPa  11  0.17  35 
 
 
Analyzing differential pore volume plot (Fig. 4), derivatives dV/d(log r) as a function 
of r, it is possible to completely define the pore distribution in the system. This function 
connects the pore diameter and partition of corresponding pores, for each discrete value of 
pore diameter.  
   Differential pore volume in tablet 1 is significantly higher than that in tablet 2, thus 
faster drug release is expected from tablet 1 (Fig. 4.). 
Pore size distribution and their partition to the total pore volume are given in a 
histogram (Fig.5.) for easier comparisons. B. Čolović et al. /Science of Sintering, 45 (2013) 107-116 
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Fig. 4. Differential pore volume 
 
   
 
 
Fig. 5. Pore size distribution and their partition for tablet 1 and 2 
 
Multimodal distribution of pore sizes can be observed in Fig.5. It derives from 
different types of pores: the largest pores formed during tablet compression, large pores 
between aggregates, pores between particles, small pores between smaller particles arranged 
inside of the agglomerates and the smallest pores between basic particles. Comparing pore 
sizes in tablet 1 (p=16 MPa) and tablet 2 (p=156 MPa), it is evident that the pores in tablet 2 
are significantly smaller. In tablet 2, the smallest pores (10-20 nm) contribute in total pore 
volume with 36 %, while in tablet 1 with only 1.2 %. The most dominant pores in tablet 2 are 
those with diameters of 20-30 nm, while in tablet 1 those with diameters of 60-80 nm.  
 
3.4. Drug release from tablets 
 
Release profiles of tigecycline from tablets, compressed with different pressures, are 
shown in Fig.6. The drug release occurs in two stages: first stage is characterized by a fast 
initial release, and the second by a continuous slow release. This initially high release rate 
might be of great importance, because the drug effectiveness is often much higher when its 
concentration at the infection site at the beginning of a therapy is high. B. Čolović et al./Science of Sintering, 45 (2013) 107-116 
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Fig. 6. Release profile of tigecycline 
 
As expected, Higuchi’s equation can be applied to the experimental data only when 
about 60 % of drug has been released. In the case of tablet 1, this equation fits to the 
experimental data for the period of the first 5 hours when 67% of the total drug amount was 
released, and in the case of tablet 2, for the period of the first 50 h when 60 % of the drug was 
released.      
 
Fig. 7. Fitting data by Higuchi’s equation 
                                                                                                                                                                                        
Appling the Korsmeyer-Peppas equation, in logarithmic form, to tablet 1 data, the 
same was confirmed, i.e., it fits the data for the initial period of release only, when 67% of the 
total drug quantity was released (Fig.8.). The coefficient of direction of the linear part of the 
curve is 0.5, which is also the value of the exponent n. The value of n=0.5 indicates that the 
Korsmeyer-Peppas equation is reduced to the Higuchi equation (relative release rate 
proportional to the square root of time). But, as shown, it fits the data for tablet 2 over the 
whole period of drug release (Fig.8.).  B. Čolović et al. /Science of Sintering, 45 (2013) 107-116 
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Fig. 8. Fitting data by Korsmeyer-Peppas model 
 
As hydroxyapatite used for fabrication of tablets has a very complex structure 
(agglomerates (1-5 µm), particles (200 nm), subparticles (160 nm), crystallites (8-22 nm)), the 
drug release rate can be correlated with the corresponding geometry of apatite particles. 
Therefore, the relationship between the hierarchical porosity of tablets and the drug release 
rate was taken as the most essential factor, which has to be carefully analyzed to obtain 
precise and practical information that would facilitate the designing of various delivery 
systems for controlled drug release by selecting their optimal geometry.  
The tablet porosity data, presented in Fig.5, can be easily correlated with the 
corresponding drug release rates interpreted by Korsmeyer-Peppas model and given in Fig.8.  
In the case of tablet 2 (Fig.8.) we have narrow pore size distribution (10-50 nm) so 
drug release rate is quite uniform and Korsmeyer-Peppas equation fits the experimental data 
over the whole period of drug release (R
2=0.993). The coefficient of direction gives the value 
of release exponent of 0.3. 
Opposed to narrow pore size distribution in tablet 2, pore size distribution in tablet 1 
is much wider (10-180 nm). Therefore, the kinetics of drug release in this sample can not be 
described with only one equation. If we observe separately release from the various pores, 
conditionally named large (60-180 nm), medium (30-60 nm) and small (10-30 nm), then the 
release kinetics can be described more preciously. Accordingly, the drug release curve for 
tablet 1 (Fig.8.) can be divided into three linear segments. Each of these segments has 
different coefficient of direction, which can be assigned to the corresponding drug release 
rate. Thus, the release is the fastest at the initial stage (coefficient n = 0.5) and is related to the 
largest pores (with diameter of 60-180 nm and contribution to the total pore volume of 71%). 
During this period (5 hours), the amount of drug released was approximately 67%. During the 
next 20 hours, the drug release rate is lower (n = 0.18). The quantity of drug released (about 
23%) can be associated with the pores 40-60 nm in diameter (20% of the total pore volume). 
And finally, the last linear segment, which covers the period of 97 h, shows the lowest release 
rate (n = 0.008). During this time 10% of the total drug quantity was released. This quantity 
can be associated with the release from the smallest pores with diameters of 10-40 nm (9% of 
the total pore volume).  
The presented data show that, within any linear interval, the percentage of drug 
released and the percentage of pores of certain sizes present in the sample is approximately 
the same. Thus, it follows that the geometry (porosity) is of great importance for the drug 
release kinetics, and has to be therefore further examined.  B. Čolović et al./Science of Sintering, 45 (2013) 107-116 
___________________________________________________________________________ 
 
115
 
4. Conclusions 
 
A new approach to the interpretation of the mechanism of drug release from ceramic 
materials, which determines the relationship between pore sizes and the drug release rate, was 
given in this study. Korsmeyer-Peppas model was applied in a modified procedure in order to 
determine relations between pore sizes, their distribution and drug release rate. This enabled 
quantification of drug release kinetics based on porosity parameters of the used ceramic 
device. 
It has been shown here that it is possible to predict the rate of drug release from any 
ceramic device if its porosity is precisely determined. 
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Садржај: Кинетика отпуштања тигециклина, потенцијалног антибиотика за лечење 
остеомијелитиса,  из  калцијум  хидроксиапатита,  као  једног  од  најважнијих 
материјала у инжењерству коштаног ткива, испитивана је у овом раду. Тигециклин, у 
прашкастом облику, помешан је са прахом ХАП-а и од добијене смеше направљене су 
таблете,  пресовањем  под  два  различита  притиска.  Ове  таблете  су  уроњене  у 
фосфатни пуфер и отпуштање тигециклина је мерено УВ-ВИС спектрофотометра. 
Укупно време отпуштања било је 5 или 28 дана, у зависности од примењеног притиска 
пресовања.  Показало  се  да  постоји  блиска  веза  између  величине  пора  и  брзине 
отпуштања лека. Кинетика отпуштања лека је интерпретирана са аспекта величине 
пора и расподеле величине пора. 
Кључне речи: хидроксиапатит, геометрија пора, отпуштање лека  
 
 